NCT07407062Recruiting
A Study to Evaluate Folate Receptor Alpha (FRα) Expression in Adult Participants With Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in Italy
Folate Receptor Alpha Expression in Relapsed Ovarian, Fallopian Tube and Primary Peritoneal Cancer: a Realworld prEvalence Study in Italy
Source: ClinicalTrials.gov · Last updated 27 Jul 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the prevalence of folate receptor alpha (FRα)-positive status (≥75% viable tumor cells with moderate (2+) and/or strong (3+) membrane staining) in participants with high-grade serous ovarian, fallopian tube, and primary peritoneal cancer, stratified by time of sampling (initial diagnosis versus relapse), adhering to Ventana folate receptor alpha (FOLR1) RxDx (prescription diagnosis) assay Interpretation Guidance.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 6 Feb 2026
- Start date
- 26 Jun 2026
- Primary completion date
- Nov 2026
- Lead sponsor
- AbbVie
- Diseases
- Ovarian cancer
- NCT number
- NCT07407062
What you commit to
- Study type: Observational
- Planned participants: 200
- From 26 Jun 2026 to the primary completion date, Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Diagnosis based on cytology and without any biopsy or surgical specimen
Other illness
- Other histotypes than high grade serous ovarian cancer, fallopian tube cancer and primary peritoneal cancer
Other
- Histological ambiguous diagnosis upon review
- Archival or recurrent sample for the same participant not available
Who the study is looking for
- Relapsed ovarian, fallopian tube and primary peritoneal cancer
- Histologically high-grade serous carcinoma
- Presence of archived surgical tissue samples from participants with epithelial ovarian cancer at diagnosis and at 1st recurrence in the same participants
- Available samples collected from January 1st, 2016 to study start date (defined as study site initiation visit date) that are considered adequate for the Ventana folate receptor alpha (FOLR1) RxDx assay by the site pathologist
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Universita Cattolica /ID# 280205 Coordinator of this site? Confirm its status | Rome | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.